<DOC>
	<DOCNO>NCT01779908</DOCNO>
	<brief_summary>Prospective , randomized placebo-controlled 6-month trial vitamin D supplementation 130 Caucasian vitamin D-deficient men woman age 25 year . Participants abdominal obesity least one factor associate insulin resistance . Participants randomize sex , BMI age . The primary aim compare effect daily vitamin D3 ( cholecalciferol , 5000 IU ) vs. placebo 6 mo insulin sensitivity ( M-value gold standard method , euglycemic hyperinsulinemic clamp ) . Secondary aim evaluate effect vitamin D3 vs. placebo index glucose metabolism , lipid profile , blood pressure anthropometric measurement . Questionnaires physical activity sunlight exposure , food frequency questionnaire administer 0 6 mo adjust confound factor . At 0 6 mo , change serum 25 ( OH ) D correlate change blood marker associate insulin sensitivity [ hs-CRP , inflammatory cytokine ( IL-6 TNF-alpha ) , adiponectin , leptin , total undercarboxylated osteocalcin ] . This research project intend test 2 major hypothesis : ( 1 ) vitamin D deficiency play causal role pathogenesis insulin resistance human ; ( 2 ) vitamin D increase insulin sensitivity .</brief_summary>
	<brief_title>Role Vitamin D Prevention Treatment Diseases Associated With Insulin Resistance</brief_title>
	<detailed_description>Part 1 : Prospective , randomized placebo-controlled 6-month trial vitamin D supplementation 130 Caucasian vitamin D-deficient [ serum 25 ( OH ) D ≤55 nM ] men woman age 25 year BMI ≤40 kg/m2 . Participants abdominal obesity ( increased waist circumference least 102 cm men 88 cm woman ) least one factor associate insulin resistance , namely : ( 1 ) serum triglyceride level least 1.7 mmol/L treat dyslipidemia ; ( 2 ) prediabetes untreated type 2 diabetes ( HbA1c &gt; =5.6 % fast glucose &gt; =5.6 mmol/L glucose 2h post OGTT &gt; =7.8 mmol/L ) ; ( 3 ) first degree relative type 2 diabetes ; ( 4 ) history gestational diabetes . Participants randomize accord sex , BMI ( &lt; 30 kg/m2 vs. 30 kg/m2 ) age ( &lt; &gt; =50 year old ) . The primary aim compare effect daily vitamin D3 ( cholecalciferol , 5000 IU ) vs. placebo 6 mo insulin sensitivity ( M-value gold standard method , euglycemic hyperinsulinemic clamp ) . Secondary aim evaluate effect vitamin D3 vs. placebo index glucose metabolism ( fast glucose , 2-h plasma glucose post OGTT , HbA1c , insulin sensitivity index ( HOMA-IS use fast glucose insulin ) , insulin secretion index ( HOMA-B use fast glucose C-peptide ) , insulinogenic index [ ( C-peptide 30 min post OGTT - C-peptide 0 min ) / ( glucose 30 min post OGTT - glucose 0 min ) ] disposition index ( insulinogenic index x M-value ) ) , lipid profile , blood pressure anthropometric measurement ( weight , waist hip circumference , bioimpedance analysis ) . Questionnaires physical activity sunlight exposure , food frequency questionnaire administer 0 6 mo adjust confound factor . At 0 6 mo , biochemical marker associate insulin sensitivity measure ( point 2 ) . Part 2 : Mechanistic study compare , vitamin D3 supplementation , change serum 25 ( OH ) D change blood marker associated insulin sensitivity [ hs-CRP , inflammatory cytokine ( IL-6 TNF-alpha ) , adiponectin , leptin , total undercarboxylated osteocalcin ] .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Caucasian men woman ≥25 yrs vitamin D deficiency [ serum 25 ( OH ) D concentration ≤55 nM ] Abdominal obesity ( waist circumference &gt; =102 cm men &gt; =88 cm woman ) AND least one factor associate insulin resistance : ( 1 ) fast serum triglyceride &gt; =1.7 mmol/L treat dyslipidemia ; ( 2 ) prediabetes untreated type 2 diabetes ( HbA1c &gt; =5.6 % fast glucose &gt; =5.6 mmol/L 2h glucose post OGTT &gt; =7.8 mmol/L ) ; ( 3 ) first degree relative type 2 diabetes ; ( 4 ) history gestational diabetes . Type 2 diabetes drug therapy HbA1c &gt; 7 % BMI &gt; 40 kg/m2 pregnancy breastfeeding ; medication influence vitamin D glucose metabolism last 3 mo regular consumption supplement contain &gt; 400 IU/d vitamin D3 last 2 mo ; renal insufficiency ( creatinine clearance &lt; 60 ml/min ) ; cirrhosis , intestinal malabsorption ( bypass surgery , celiac disease , etc ) ; osteoporosis ; history nephrolithiasis ; hypercalcemia ( &gt; 2.6 mM ) ; hypercalciuria ( &gt; 0.6 fast urine Ca/creatinine ratio ) ; &gt; 5 % change weight last 3 mo ; diseases affect glucose metabolism ( e.g . hyperthyroidism ) ; pacemaker ( bioimpedance ) ; inability provide inform consent complete questionnaire due physical mental problem .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Vitamin D supplementation</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>